[Bone status in primary hyperparathyroidism].
Fujiyama
Kaoru
K
Division of Physiology of Visceral Function and Body Fluid, Department of Translational Medical Sciences, Graduate School of Biomedical Sciences, Nagasaki University.
D000814:Aniline Compounds / Q000627:therapeutic use; D015519:Bone Density; D001862:Bone Resorption / Q000209:etiology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D016105:Parathyroidectomy; D010627:Phenethylamines; D011437:Propylamines; D012306:Risk
D000814:Aniline Compounds; D004164:Diphosphonates; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines